Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability is a research paper published in European Journal of Medicinal Chemistry (2023). On theSindex it has a DataRank of 0.269. It has been cited 5 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.269
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: P30 CA051008
NCI NIH HHS
Grant: T32 CA009686
Henry Luce Foundation
Bone Cancer Research Trust
Children's Cancer Foundation
NIH
FWCI
0.46
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
BindingDB Entry 50019846: Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability.